Exelixis Financials
EXEL Stock | USD 35.26 0.33 0.93% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 2.9 | 5.4348 |
|
|
Investors should never underestimate Exelixis' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Exelixis' cash flow, debt, and profitability to make informed and accurate decisions about investing in Exelixis.
Net Income |
|
Exelixis | Select Account or Indicator |
Understanding current and past Exelixis Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Exelixis' financial statements are interrelated, with each one affecting the others. For example, an increase in Exelixis' assets may result in an increase in income on the income statement.
Exelixis Earnings Geography
Exelixis Stock Summary
Exelixis competes with TG Therapeutics, Viking Therapeutics, Madrigal Pharmaceuticals, BioXcel Therapeutics, and Biomarin Pharmaceutical. Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. Exelixis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 954 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US30161Q1040 |
CUSIP | 30161Q104 |
Location | California; U.S.A |
Business Address | 1851 Harbor Bay |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.exelixis.com |
Phone | 650 837 7000 |
Currency | USD - US Dollar |
Exelixis Key Financial Ratios
Return On Equity | 0.2 | ||||
Profit Margin | 0.22 % | ||||
Operating Margin | 0.35 % | ||||
Price To Sales | 4.88 X | ||||
Revenue | 1.83 B |
Exelixis Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.9B | 2.1B | 2.6B | 3.1B | 2.9B | 3.1B | |
Retained Earnings | (559.4M) | (447.6M) | (216.5M) | (34.2M) | (173.4M) | (182.0M) | |
Other Current Liab | 21.7M | 179.2M | 313.3M | 284.2M | 360.5M | 378.5M | |
Net Debt | (215.8M) | (270.1M) | (595.9M) | (311.0M) | (73.1M) | (69.4M) | |
Accounts Payable | 11.6M | 23.6M | 24.3M | 32.7M | 33.8M | 35.5M | |
Cash | 266.5M | 319.2M | 647.2M | 501.2M | 263.0M | 190.9M | |
Net Receivables | 119.1M | 160.9M | 282.7M | 214.8M | 237.4M | 249.3M | |
Other Current Assets | 27.0M | 57.0M | 57.5M | 62.2M | 67.9M | 71.3M | |
Total Liab | 199.7M | 258.2M | 405.6M | 583.1M | 678.4M | 370.3M | |
Total Current Assets | 1.0B | 1.4B | 1.8B | 1.6B | 1.3B | 1.4B | |
Short Term Debt | 2.7M | 3.0M | 8.7M | 17.7M | 25.7M | 50.4M | |
Common Stock | 305K | 312K | 319K | 324K | 303K | 287.9K | |
Other Liab | 8.9M | 4.5M | 16.8M | 68.5M | 78.8M | 83.4M | |
Other Assets | 185.3M | 187.1M | 197.5M | 286.9M | 329.9M | 346.4M | |
Inventory | 12.9M | 21.0M | 27.5M | 33.3M | 17.3M | 9.5M | |
Net Tangible Assets | 1.6B | 1.8B | 2.0B | 2.4B | 2.8B | 2.9B | |
Capital Surpluse | 2.2B | 2.2B | 2.3B | 2.5B | 2.9B | 2.1B |
Exelixis Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Revenue | 967.8M | 987.5M | 1.4B | 1.6B | 1.8B | 1.9B | |
Gross Profit | 934.7M | 951.3M | 1.4B | 1.6B | 1.8B | 1.8B | |
Operating Income | 369.5M | 110.1M | 286.7M | 201.5M | 170.9M | 179.4M | |
Ebit | 369.5M | 110.1M | 286.7M | 201.5M | 170.9M | 179.4M | |
Research Development | 337.0M | 547.9M | 693.7M | 891.8M | 1.0B | 1.1B | |
Ebitda | 377.8M | 119.2M | 300.3M | 222.4M | 196.6M | 206.4M | |
Income Before Tax | 398.1M | 130.8M | 294.2M | 234.4M | 257.5M | 270.4M | |
Net Income | 321.0M | 111.8M | 231.1M | 182.3M | 207.8M | 218.2M | |
Cost Of Revenue | 33.1M | 36.3M | 52.9M | 57.9M | 72.5M | 55.5M | |
Income Tax Expense | 77.1M | 19.1M | 63.1M | 52.1M | 49.8M | 52.2M | |
Net Interest Income | 28.0M | 19.9M | 7.7M | 33.1M | 82.1M | 86.3M | |
Tax Provision | 77.1M | 19.1M | 63.1M | 52.1M | 31.0M | 32.5M | |
Interest Income | 28.0M | 19.9M | 7.7M | 33.1M | 82.1M | 86.3M |
Exelixis Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (47.7M) | 52.6M | 343.1M | (161.2M) | (239.7M) | (227.7M) | |
Free Cash Flow | 514.1M | 178.6M | 336.6M | 224.2M | 170.4M | 178.9M | |
Depreciation | 8.3M | 9.1M | 13.6M | 20.9M | 25.7M | 27.0M | |
Capital Expenditures | 12.8M | 30.3M | 64.2M | 138.5M | 163.0M | 171.1M | |
Net Income | 321.0M | 111.8M | 231.1M | 182.3M | 207.8M | 218.2M | |
End Period Cash Flow | 268.1M | 320.8M | 663.9M | 502.7M | 263.0M | 191.9M | |
Change To Inventory | (5.7M) | (21.9M) | (13.2M) | (11.7M) | (13.0M) | (12.3M) | |
Other Non Cash Items | 2.9M | 7.9M | 28.8M | 125.0M | 140.7M | 147.7M | |
Investments | (574.4M) | (100.9M) | 21.3M | (386.0M) | (334.5M) | (317.8M) | |
Change Receivables | (89.9M) | 43.7M | (42.5M) | 66.8M | 76.9M | 80.7M | |
Change To Netincome | 127.7M | 123.4M | 195.1M | 153.9M | 177.0M | 185.9M |
Exelixis Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Exelixis's current stock value. Our valuation model uses many indicators to compare Exelixis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Exelixis competition to find correlations between indicators driving Exelixis's intrinsic value. More Info.Exelixis is rated # 3 in return on equity category among its peers. It is rated # 2 in return on asset category among its peers reporting about 0.63 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Exelixis is roughly 1.58 . At this time, Exelixis' Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Exelixis by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Exelixis Systematic Risk
Exelixis' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Exelixis volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Exelixis correlated with the market. If Beta is less than 0 Exelixis generally moves in the opposite direction as compared to the market. If Exelixis Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Exelixis is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Exelixis is generally in the same direction as the market. If Beta > 1 Exelixis moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Exelixis Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Exelixis' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Exelixis growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Exelixis December 3, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Exelixis help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Exelixis. We use our internally-developed statistical techniques to arrive at the intrinsic value of Exelixis based on widely used predictive technical indicators. In general, we focus on analyzing Exelixis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Exelixis's daily price indicators and compare them against related drivers.
Downside Deviation | 1.39 | |||
Information Ratio | 0.1589 | |||
Maximum Drawdown | 14.75 | |||
Value At Risk | (1.84) | |||
Potential Upside | 3.14 |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 121.699 | Earnings Share 1.55 | Revenue Per Share 7.032 | Quarterly Revenue Growth 0.143 | Return On Assets 0.1281 |
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.